Sep 29, 2020 4:05pm EDT Tonix Pharmaceuticals Announces Plan to Complete the Phase 3 RELIEF Study of TNX-102 SL for Management of Fibromyalgia with Currently Enrolled Participants Based on Results of Interim Analysis
Sep 28, 2020 4:15pm EDT Tonix Pharmaceuticals Completes Purchase of Facility to House Advanced Development Center (ADC) for Vaccine Programs
Sep 17, 2020 9:17am EDT Tonix Pharmaceuticals to Host Live Webinar: Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19?
Sep 15, 2020 9:00am EDT Tonix Pharmaceuticals Enrolls First Patient in COV-LOGIC, an Observational Study to Assess Antibody and T Cell Responses to SARS-CoV-2, the Virus that Causes COVID-19
Sep 3, 2020 9:00am EDT Tonix Pharmaceuticals Initiates Enrollment in Second Potentially Pivotal Phase 3 Study, the RALLY Study, of TNX-102 SL for the Management of Fibromyalgia
Aug 27, 2020 7:30am EDT Tonix Pharmaceuticals to Participate in Upcoming September Virtual Investor Conferences
Aug 10, 2020 8:45am EDT Tonix Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights
Aug 6, 2020 9:00am EDT Tonix Pharmaceuticals Announces Clearance of IND for TNX-102 SL for Treatment of Alcohol Use Disorder
Aug 4, 2020 9:00am EDT Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
